Spelling suggestions: "subject:"pharmacovigilance."" "subject:"pharmacovigillance.""
91 |
Reações adversas a medicamentos: coorte de pacientes ortopédicos / Adverse drug reactions: cohort of orthopedic patientsTathiana Silva de Souza Martins 08 September 2015 (has links)
Introdução: Reação Adversa a Medicamento (RAM) é qualquer resposta prejudicial ou indesejável e não intencional que ocorre com medicamentos em doses normalmente utilizadas no homem para profilaxia, diagnóstico, tratamento de doença ou para modificação de funções fisiológicas. Atualmente, representa uma das principais causas de morbidade e mortalidade na área da saúde. Objetivo: Analisar as reações adversas a medicamentos e fatores associados em pacientes ortopédicos tratados com antibióticos. Método: Coorte prospectiva conduzida com 273 pacientes ortopédicos internados no Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, Brasil. A coleta de dados ocorreu nos anos de 2012 e 2013, por meio de instrumento composto por variáveis demográficas-clínicas e terapia medicamentosa. Para identificação das RAMs realizou-se o monitoramento ativo, composto de: entrevista, análise de prontuários e exames laboratoriais. As RAMs consideradas graves foram analisadas por meio do formulário do Instituto Catalão de Farmacologia, Espanha. Na análise dos dados utilizaram-se os testes Mann-Whitney, Qui-Quadrado, exato de Fisher e regressão logística, com significância de p 0,05. Resultados: A incidência de RAM foi de 41%. O grupo com RAM apresentou maior média de idade (43,3; DP 10,9), tempo de internação (72,7; DP 40,9) e número de medicamentos concomitantes (13,2; DP 4,1). Os fatores associados foram número de medicamentos, uso de antimicobacteriano (OR 2,44; IC 1,3944,270) e carbapenêmicos (OR 2,38; IC 1,167 4,872). Identificaram-se 466 RAM, cuja maioria (67,1%) foi classificada como leve. No grupo de pacientes com RAMs graves identificaram-se leucopenia (46,6%), insuficiência renal aguda (40%) e hepatite medicamentosa (26,6%). Os antibióticos foram os principais medicamentos suspeitos de causar as RAMs graves (76,4%), sendo os mais frequentes (23,5%) formados pela tríade: amicacina + vancomicina + piperacilina com tazobactam. Conclusão: A incidência de RAM é maior quando se incorpora ao serviço de farmacovigilância a técnica de monitoramento contínuo dos pacientes hospitalizados e se utiliza a analise de exames laboratoriais como preditores para suspeitas de RAMs potencialmente graves / Introduction: Adverse Drug Reaction (ADR) is any noxious, undesired or unintended response which occurs in the use of normal dosages of drugs for prophylaxis, diagnosis, treatments or for modifying physiologic functions. Nowadays, ADR represents one of the main causes of morbidity and mortality in the health service area. Objective: To analyze the occurrence of adverse reaction to drugs and factors related to orthopedic patients treated with antibiotics. Method: The prospective cohort study was conducted in 273 orthopedic patients hospitalized at the Brazilian Institute of Traumatology and Orthopedics in Rio de Janeiro. The data collection was made during the years 2012 and 2013, using instruments composed by demographic-clinical variables and drug therapies. With the purpose of identifying occurrences of ADRs, during active monitoring, interviews were conducted, medical charts and exams were analyzed. In addition, the occurrence of ADRs considered harmful was analyzed by using a form provided by the Catalan Institute of Pharmacology, Spain. In the study of the data collected, was made use of Mann-Whitney tests, Chi-Squared test, Fishers exact test and logist regression, with p-value 0,05. Results: The occurrence of ADRs was of 41%. This group was composed by individuals with major age rage (43,3, SD 10,9), major time spent hospitalized (72,7; SD 40,9), and quantity of concurrent drugs used (13,2; SD 4,1). Also, the related factors were the number of drugs, the usage of Antimicobacterial agents (OR 2,44, CI 1,394-4,270) and Carbapenemases (OR 2,38; CI 1,167 4,872). During the study, there were identified 466 ADRs, and the majority (67,1%) was classified as low-grade. Additionally, in the group of patients with harm adverse reactions, it was possible to identify leukopenia (46,6%), acute kidney failure (40%) and drug-induced hepatitis (26,6%). The antibiotics were the main drugs suspected to be the cause of potentially harmful ADRs (76,4%), being the most frequent (23,5%) formed by the triad: amikacin + vancomycin + piperacillin-tazobactam. Conclusion: The occurrence of ADRs is higher when the practice of continuous monitoring of hospitalized patients is incorporated to the pharmacovigilance service, and the analyzes of lab exams are used as predictors for the suspicion of potentially harmful ADRs
|
92 |
Farmacovigilância no tratamento com peginterferon e ribavirina em pacientes com hepatite C crônica no serviço de hepatologia do Hospital Universitário de Aracaju-SE / PHARMACOVIGILANCE IN THE TREATMENT WITH PEGINTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C IN THE SERVICE OF HEPATOLOGY AT UNIVERSITY HOSPITAL IN ARACAJU-SE.Nogueira, José Barreto Cruz 30 March 2011 (has links)
Hepatitis C is an infectious disease with an overall prevalence of 2.2% and Brazil 1.5%. Drug therapy consists of interferon α, peginterferon α and ribavirin. It is filled with aggressive treatment of adverse reactions, hence the importance of pharmacovigilance as an additional tool in monitoring the treatment and rational use of medicines. Thus, adverse reactions occurred in patients with chronic hepatitis C who were treated with peginterferon and ribavirin, were identified and quantified through a retrospective and observational study. The most prevalent reactions observed in 46 patients in the study, were: fatigue (84.8%), fever (82.6%), loss weight (80.4%), irritability (73.9%) and body pain (71.7%). Most reactions were classified as mild (95.1%), while like moderate, 4.5% and as serious, 0.4%. The adverse reactions caused the therapeutic management in 11 patients (23.9%) where it was, dose reduction for 7 patients (15.2%), temporary discontinuation of the treatment for 5 patients (10.9%) and permanent discontinuation for 3 patients (6.5%).
Eleven potential drug interactions were identified in 9 patients (19.6 %), where the most frequent was among peginterferon α 2a and captopril (45.4%). Said that, it s
noticed that the treatment for chronic hepatitis C is marked for many adverse reactions with variable severity, that may interfere on patient s quality of life or in compliance of the treatment and this may be exacerbated by potential drug interactions. Additionally we evaluated the pharmacovigilance system of the
Hepatology service of the University Hospital of the Federal University of Sergipe of patients registered from January 2007 to July 2009. / A hepatite C é uma doença infecciosa, com prevalência global de 2,2% e no Brasil de 1,5%. A terapêutica medicamentosa é constituída pelo interferon α,
peginterferon α e a ribavirina. É um tratamento agressivo repleto de reações adversas, daí a importância da farmacovigilância como ferramenta adicional no acompanhamento do tratamento e do uso racional dos medicamentos. Assim, Reações adversas ocorridas em pacientes com hepatite C crônica tratados com peginterferon e ribavirina foram identificadas, quantificadas e classificadas através de um estudo retrospectivo e observacional. As reações mais prevalentes observadas nos 46 pacientes do estudo foram: astenia (84,8%), febre (82,6%), perda de peso
(80,4%), irritabilidade (73,9%) e dor no corpo (71,7%). A maior parte das reações foi classificada como leve (95,1%), enquanto que como moderada, 4,5% e como graves, 0,4%. As reações adversas acarretaram o remanejamento terapêutico de 9 pacientes (19,6%) nos quais houve, redução da dose para 7 (15,2%), interrupção temporária do tratamento para 5 (10,9%) e interrupção permanente para 3 pacientes (6,5%). Onze
interações medicamentosas potenciais foram identificadas em 9 pacientes (19,6 %), nos quais a mais freqüente foi entre o peginterferon α 2a e o captopril (45,4%). Diante do exposto, observa-se que o tratamento para hepatite C crônica é marcado por várias reações adversas, de gravidade variável, que podem interferir na qualidade de vida do paciente ou no cumprimento do tratamento e que isto pode ser agravado pelas potenciais interações medicamentosas. Adicionalmente se avaliou o sistema de farmacovigilância do Ambulatório de Hepatologia do Hospital Universitário da Universidade Federal de Sergipe dos pacientes cadastrados de janeiro de 2007 a julho de 2009.
|
93 |
UtilizaÃÃo da flutamida em indicaÃÃes nÃo aprovadas pela ANVISA: aspectos referentes à seguranÃa, efetividade, avaliaÃÃo do risco e estratÃgias para contornÃ-lo. / Use of Flutamide on indications not approved by ANVISA - aspects concerning the safety, effectiveness, risk assessment and strategies to circumvent it.PatrÃcia Mandali de Figueiredo 30 April 2004 (has links)
Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / nÃo hà / A Flutamida à um medicamento anti-androgÃnico nÃo esterÃide aprovado para o tratamento do cÃncer de prÃstata. Seu efeito hepatotÃxico foi conhecido desde o inÃcio do perÃodo de comercializaÃÃo, hà mais de 10 anos. Em marÃo e junho de 2002, a Unidade de FarmacovigilÃncia da ANVISA recebeu as primeiras comunicaÃÃes de Ãbitos por hepatite fulminante associados ao uso da substÃncia (medicamento manipulado) em jovens do sexo feminino. A literatura mundial nunca registrara caso semelhante. O objetivo deste trabalho foi revisar e acrescentar informaÃÃes a respeito da seguranÃa da Flutamida quando utilizadas por pacientes do sexo feminino para o tratamento de hirsutismo, acne e alopecia androgenÃtica. Foram realizadas pesquisas para conhecer a indicaÃÃo aprovada em outros paÃses e as notificaÃÃes de reaÃÃes adversas graves em mulheres no banco de dados da OMS. AlÃm disso, por meio de busca ativa, tentou-se identificar outros casos no Brasil; rever as informaÃÃes das bulas de todos os medicamentos comercializados e analisar se as informaÃÃes obrigatÃrias e relevantes para diminuir o risco de reaÃÃes hepÃticas graves estavam presentes. Por fim, foi realizada pesquisa com os prescritores, por meio de questionÃrio eletrÃnico, para conhecer as informaÃÃes de que dispunham sobre a utilizaÃÃo do medicamento em mulheres e comparar estas informaÃÃes com uma revisÃo crÃtica da literatura no que tange à seguranÃa e eficÃcia. Os resultados de todas estas estratÃgias mostraram que a substÃncia tambÃm à utilizada off label em mulheres em outros paÃses, e tambÃm causou reaÃÃes adversas graves, mas nenhum Ãbito no sexo feminino fora relatado. Durante o trabalho, outros casos de Ãbito no Brasil foram identificados. Todas as bulas comercializadas no Brasil mencionavam que a substÃncia nÃo devia ser utilizada por mulheres, assim como mencionavam as reaÃÃes hepÃticas graves. As respostas dos prescritores ao questionÃrio permitem afirmar que a Flutamida se constitui em importante arsenal terapÃutico, e que o risco de seu uso vem sendo subestimado. O trabalho permite concluir que a Flutamida mostra-se eficaz para as condiÃÃes em que vem sendo utilizada em mulheres. Entretanto, os riscos evidenciam uma relaÃÃo benefÃcio/risco inaceitÃvel para as condiÃÃes estÃticas em que vem sendo empregada. / Flutamide is a non steroid anti-androgenic drug used to treat prostate cancer patients. When it became commercialized, more than 10 years ago, the hepatotoxic effect of flutamide was already recognized. In March and July 2002, the first cases of deaths in young females caused by fulminant hepatitis associated to off label use of this substance (magistral drug) was reported to the Pharmacovigilance Office/ANVISA. Up to now, similar cases were not described in the international literature. This work aimed to review and add information about the adequate use of flutamide by female patients to treat hirsutism, acne and androgenetic alopecia. To identify the standard prescriptions and the reported serious reactions in females worldwide, an extensive research through data provided by OMS was conducted. Moreover, using active search we looked for new local cases and review the information from package insert of all commercialized drugs in Brazil to analyze if the required and relevant information warning patients against the serious hepatic risks were provided. Finally, a survey with the prescribers was carried on through the web to identify the available information about the use of this drug in females and to make comparisons with data from the literature about the safety and efficacy of the use of this substance. The results showed that this substance is also used off label by women from other countries, who also presented serious adverse reactions. However, it was not reported any case of female death. Over the study, new cases of obituary occurred in Brazil, despite all analyzed package insert explain that this substance should not be used by females and mention serious hepatic reactions. The answers of the prescribers to the survey indicated that flutamide is an important therapeutic arsenal and that the risk of the use of this substance seem to have been underestimated. We concluded that flutamide is effective for the women treatment which it has been used. However, the threats of this drug point to the unacceptable use of this drug when applied for the esthetic finality.
|
94 |
Improving the speed and quality of an Adverse Event cluster analysis with Stepwise Expectation Maximization and Community DetectionErlanson, Nils January 2020 (has links)
Adverse drug reactions are unwanted effects alongside the intended benefit of a drug and might be responsible for 3-7\% of hospitalizations. Finding such reactions is partly done by analysing individual case safety reports (ICSR) of adverse events. The reports consist of categorical terms that describe the event.Data-driven identification of suspected adverse drug reactions using this data typically considers single adverse event terms, one at a time. This single term approach narrows the identification of reports and information in the reports is ignored during the search. If one instead assumes that each report is connected to a topic, then by creating a cluster of the reports that are connected to the topic more reports would be identified. More context would also be provided by virtue of the topics. This thesis takes place at Uppsala Monitoring Centre which has implemented a probabilistic model of how an ICSR, and its topic, is assumed to be generated. The parameters of the model are estimated with expectation maximization (EM), which also assigns the reports to clusters. The clusters are improved with Consensus Clustering that identify groups of reports that tend to be grouped together by several runs of EM. Additionally, in order to not cluster outlying reports all clusters below a certain size are excluded. The objective of the thesis is to improve the algorithm in terms of computational efficiency and quality, as measured by stability and clinical coherence. The convergence of EM is improved using stepwise EM, which resulted in a speed up of at least 1.4, and a decrease of the computational complexity. With all the speed improvements the speed up factor of the entire algorithm can reach 2 but is constrained by the size of the data. In order to improve the clusters' quality, the community detection algorithm Leiden is used. It is able to improve the stability with the added benefit of increasing the number of clustered reports. The clinical coherence score performs worse with Leiden. There are good reasons to further investigate the benefits of Leiden as there were suggestions that community detection identified clusters with greater resolution that still appeared clinically coherent in a posthoc analysis.
|
95 |
Analýza spontánního hlášení nežádoucích účinků hormonální antikoncepce a hormonální substituční terapie / Analysis of spontaneous adverse drug reactions reporting hormonal contraception and hormone replacement therapyRyndová, Vendula January 2021 (has links)
Analysis of spontaneous adverse drug reactions reporting hormonal contraception and hormone replacement therapy Author: Vendula Ryndová Supervisor: PharmDr. Kateřina Malá, Ph.D. Consultant: PharmDr. Eva Zimčíková, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction: Hormonal contraception (HC) is the most widely used method to prevent pregnancy worldwide. In addition to pregnancy planning and other non-contraceptional benefits, it also has certain risks. Hormone replacement therapy (HRT) is used primarily for treatment of estrogen deficiency in postmenopausal women. HRT is associated with a number of risks, in particularly for women 60+ of age. Analysis of spontaneous adverse drug reactions (ADRs) reporting contribute to detection of potential risks associated with pharmacotherapy, thereby increases the safety of the drugs. Aim: The aim of this thesis was to analyse spontaneous ADRs reports of HC and HRT registered in the Czech Central Database of ADRs of the State Institute for Drug Control (SÚKL). Methods: Retrospective analysis of the spontaneous ADRs reports of HC and HRT registered in the database of SÚKL from 10/2004 to 6/2017. Mainly, method of receiving the report, reporting person, patient information, seriousness, and...
|
96 |
Competitive intelligence ve farmaceutickém průmyslu / Competitive Intelligence in pharmaceutical industryHubálková, Pavla January 2016 (has links)
This diploma thesis describes and analyzes an area of competitive intelligence in the pharmaceutical industry. The work is divided into five parts. The first part deals with competitive intelligence and related aspects, the second part is dedicated to the pharmaceutical industry, with all specifics. The third part deals with competitive intelligence in the intersection with the pharmaceutical industry, the fourth part contains the classification and description of information resources appropriate for the activities of CI and a fifth part presents research, which consists of a questionnaire survey among pharmaceutical companies on the state of competitive intelligence and semi-structured interview with an expert in the area of CI in pharmaceutical company. The survey results represent a certain sub-probe, which demonstrates the strong position of CI as a common standard of pharmaceutical companies. Keywords competitive intelligence, pharmaceutical industry, information needs, drugs, pharmacovigilance, patents, information resources
|
97 |
Development of National Drug Policy in the State of KuwaitAlali, Khaled Y.A.A January 2016 (has links)
This Thesis examines the benefits and usefulness of a National Drug Policy (NDP) for the developing of the Health Care System in Kuwait. The NDP is one of the most important structures of the Health System which can lead to improved health services by establishing guidelines, proposals and directives to organize, structure and regulate health legislation; it is of help to ensure the availability of quality, safety and efficacy in using medicines and it can reduce the irrational use of medicines. The NDP is a frame work between the government, schools and universities, media, health professionals, pharmaceutical industries and companies and public. It is cooperation between the public and private sectors to achieve the goal of access to good quality medicines for all. However there are many key factors which need to be examined before the National Drug Policy is introduced and these are considered the baseline for establishing a good policy, and includes; selection of essential drugs, affordability of drugs, drug financing, supply management, drug regulation, rational use of drugs, drugs registration, purchasing of drugs, health research and human resource development. During this research study from 2012 – 2015 several visits to the public and private health areas, were undertaken. At this time there were discussions with 121 health professionals and data was collected and this indicated that in Kuwait there are no such policies. This is despite the availability of financial means, specialized human resources and the existence of the ministerial decisions and regulations governing the health sector in both public and private, whether hospitals, health centers, pharmacies and health departments. In addition it is suggested that the process of a good NDP should be built around 3 main components which includes: 1.Development, 2. Implementation and 3. Monitoring and Evaluation. Therefore the establishing of a NDP without implementation and monitoring is not enough and does not achieve the desired results. The aim of this Thesis is to establish a NDP in the State of Kuwait. This policy is necessary for the State of Kuwait to ensure development an improvement of the Health Care System and ensure better health for population.
|
98 |
Assessment of adverse drug reactions caused by HAART at antiretroviral clinics in the Maseru district, Lesotho / Lineo Joyce MajaMaja, Lineo Joyce January 2014 (has links)
Antiretroviral drugs are successful in controlling HIV/AIDS and reducing disease progression. Antiretroviral regimens are stopped in up to 25% of all patients during their initial treatment therapy as a result of adverse drug effects, failing treatment and nonadherence within the initial eight months of treatment (Sharma et al., 2007: 235). A pharmacovigilance surveillance system makes it possible for physicians, pharmacists and other healthcare providers to report suspected ADRs. The purpose of this system is to operate as a guide in identification of new ADRs and predisposing risk factors to known ADRs.
The objective of this study was to assess the prevalence and documentation of adverse drug reactions (ADR) in the private and public antiretroviral clinics in Maseru district, with special reference to zidovudine (AZT) and tenofovir (TDF) - based regimens. The empirical investigation was divided into two phases. The first phase was a cross-sectional quantitative retrospective drug utilisation review study which focused on the occurrence of adverse drug reactions in patients taking zidovudine (AZT) and tenofovir (TDF). The second phase, a survey in a form of questionnaires for the health professionals.
Drug utilisation review: The sample size of patients was 300. Of the 44 patients who experience ADRs, 72.73% (n = 32) were female and 27.27% (n = 12) were male. A greater number of patients who experienced ADRs were females with 43.18% (n = 19) presenting with skin rash, 27.27% (n = 12) with nausea/vomiting, and 2.27% (n = 1) with diarrhoea. In male patients, 2.27% (n = 1) had peripheral neuropathy, 18.18% (n = 8) skin rash, 2.27% (n = 1) Fanconi syndrome, 2.27% (n = 1) nausea/vomiting, and 2.27% (n = 1) diarrhoea. Patients whose ART regimen changed due to ADRs were five. 60% (n = 3) of the patients were females and 40% (n = 2) were males. There was an estimated increase of 0.0025 cell/mm³, 0.0026 cell/mm³, 0.0024 cell/mm³, 0.0025 cell/mm³, and of 0.0019 cell/mm³ in CD4 cell count per day according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. An estimated increase of 0.00021 g/dL, 0.00022 g/dL, 0.00018 g/dL, 0.00022 g/dL, and of 0.00020 g/dL in Hb profile per day occurred according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. There was an estimated increase of 0.000062%, 0.000046%, 0.000068%, 0.000062%, and of 0.00017% in neutrophil count according to sex, age group, weight group, initial ART regimen, and ADRs per day, respectively. There was an estimated increase of 0.000044 IU/L, 0.000043 IU/L, 0.000046 IU/L, and of 0.000028 IU/L in ALT according to sex, age group, weight group, and initial ART regimen per day, respectively. An estimated decrease of 0.000013 IU/L in ALT according to ADRs per day also occurred. There was an estimated decrease of 0.00038 μmol/L, 0.00039 μmol/L, 0.00040 μmol/L, 0.00040 μmol/L, and of 0.00028 μmol/L in serum creatinine per day according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. There was an estimated decline of 0.00023 mmol/L, 0.00022 mmol/L, 0.00023 mmol/L, 0.00024 mmol/L, and of 0.00015 mmol/L per day in urea according to sex, age group, weight group, initial ART regimen, and ADRs, respectively.
Health professional’s questionnaire: 49 health professionals responded to the questionnaire. 100% (n= 49) of the participants showed that they did not use the yellow card scheme to report ADRs. 34.65% (n = 17) use the individual case safety reports. 57.14% (n = 28) used the structured databases to report ADRs. 85.71% (n = 42) documented in the patient bukana, and 6.12% (n = 3) used the HIV/AIDS ART card to document ADRs occurrence. 91.84% (n = 45) of the health professionals never filled the ADR reporting form in their working environment.
In conclusion, adverse drug reactions occurring in a hospital or healthcare facility should be recorded and reported by the medical practitioners, nurses, pharmacists, and the pharmacy technicians. Therefore, it is important to assess the continuous evaluation of the benefits and harm of medicines which will help in achieving the ultimate goal of making safer and more effective treatment available for patients. As well as to help the health professionals to participate in the very important process of continuous surveillance of safety and efficacy of pharmaceutical products used in clinical practice. / MPham (Pharmacy Practice), North-West University, Potchefstroom Campus, 2014
|
99 |
Assessment of adverse drug reactions caused by HAART at antiretroviral clinics in the Maseru district, Lesotho / Lineo Joyce MajaMaja, Lineo Joyce January 2014 (has links)
Antiretroviral drugs are successful in controlling HIV/AIDS and reducing disease progression. Antiretroviral regimens are stopped in up to 25% of all patients during their initial treatment therapy as a result of adverse drug effects, failing treatment and nonadherence within the initial eight months of treatment (Sharma et al., 2007: 235). A pharmacovigilance surveillance system makes it possible for physicians, pharmacists and other healthcare providers to report suspected ADRs. The purpose of this system is to operate as a guide in identification of new ADRs and predisposing risk factors to known ADRs.
The objective of this study was to assess the prevalence and documentation of adverse drug reactions (ADR) in the private and public antiretroviral clinics in Maseru district, with special reference to zidovudine (AZT) and tenofovir (TDF) - based regimens. The empirical investigation was divided into two phases. The first phase was a cross-sectional quantitative retrospective drug utilisation review study which focused on the occurrence of adverse drug reactions in patients taking zidovudine (AZT) and tenofovir (TDF). The second phase, a survey in a form of questionnaires for the health professionals.
Drug utilisation review: The sample size of patients was 300. Of the 44 patients who experience ADRs, 72.73% (n = 32) were female and 27.27% (n = 12) were male. A greater number of patients who experienced ADRs were females with 43.18% (n = 19) presenting with skin rash, 27.27% (n = 12) with nausea/vomiting, and 2.27% (n = 1) with diarrhoea. In male patients, 2.27% (n = 1) had peripheral neuropathy, 18.18% (n = 8) skin rash, 2.27% (n = 1) Fanconi syndrome, 2.27% (n = 1) nausea/vomiting, and 2.27% (n = 1) diarrhoea. Patients whose ART regimen changed due to ADRs were five. 60% (n = 3) of the patients were females and 40% (n = 2) were males. There was an estimated increase of 0.0025 cell/mm³, 0.0026 cell/mm³, 0.0024 cell/mm³, 0.0025 cell/mm³, and of 0.0019 cell/mm³ in CD4 cell count per day according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. An estimated increase of 0.00021 g/dL, 0.00022 g/dL, 0.00018 g/dL, 0.00022 g/dL, and of 0.00020 g/dL in Hb profile per day occurred according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. There was an estimated increase of 0.000062%, 0.000046%, 0.000068%, 0.000062%, and of 0.00017% in neutrophil count according to sex, age group, weight group, initial ART regimen, and ADRs per day, respectively. There was an estimated increase of 0.000044 IU/L, 0.000043 IU/L, 0.000046 IU/L, and of 0.000028 IU/L in ALT according to sex, age group, weight group, and initial ART regimen per day, respectively. An estimated decrease of 0.000013 IU/L in ALT according to ADRs per day also occurred. There was an estimated decrease of 0.00038 μmol/L, 0.00039 μmol/L, 0.00040 μmol/L, 0.00040 μmol/L, and of 0.00028 μmol/L in serum creatinine per day according to sex, age group, weight group, initial ART regimen, and ADRs, respectively. There was an estimated decline of 0.00023 mmol/L, 0.00022 mmol/L, 0.00023 mmol/L, 0.00024 mmol/L, and of 0.00015 mmol/L per day in urea according to sex, age group, weight group, initial ART regimen, and ADRs, respectively.
Health professional’s questionnaire: 49 health professionals responded to the questionnaire. 100% (n= 49) of the participants showed that they did not use the yellow card scheme to report ADRs. 34.65% (n = 17) use the individual case safety reports. 57.14% (n = 28) used the structured databases to report ADRs. 85.71% (n = 42) documented in the patient bukana, and 6.12% (n = 3) used the HIV/AIDS ART card to document ADRs occurrence. 91.84% (n = 45) of the health professionals never filled the ADR reporting form in their working environment.
In conclusion, adverse drug reactions occurring in a hospital or healthcare facility should be recorded and reported by the medical practitioners, nurses, pharmacists, and the pharmacy technicians. Therefore, it is important to assess the continuous evaluation of the benefits and harm of medicines which will help in achieving the ultimate goal of making safer and more effective treatment available for patients. As well as to help the health professionals to participate in the very important process of continuous surveillance of safety and efficacy of pharmaceutical products used in clinical practice. / MPham (Pharmacy Practice), North-West University, Potchefstroom Campus, 2014
|
100 |
Eventos adversos a medicamentos em idosos de unidades de terapia intensiva / Adverse drug events in the elderly of intensive care unitsGomes, Vanessa Rossato 07 June 2017 (has links)
Introdução: Eventos adversos a medicamentos (EAM) representam um importante problema de saúde pública, sendo associados à morbimortalidade, maior taxa de permanência hospitalar e elevação de custos. Os idosos e os pacientes de unidade de terapia intensiva (UTI) são grupos de risco para a ocorrência desses eventos. O uso de rastreadores, que representam situações indicativas de potenciais EAM, simplifica a detecção de EAM por meio do screening sistemático de prontuários, possibilitando a mensuração da taxa dessas adversidades continuamente e permitindo avançar na prática de segurança do paciente crítico. Objetivo: Analisar os eventos adversos a medicamentos e fatores associados em pacientes idosos de UTI. Método: Coorte retrospectiva conduzida com idosos internados em UTI do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. A amostra consecutiva foi composta por prontuários de idosos, hospitalizados por no mínimo 24 horas para tratamento clínico ou cirúrgico e que tenham recebido pelo menos um medicamento. Os pacientes foram acompanhados da internação até a saída da UTI por alta ou óbito. Para a identificação dos EAM utilizou-se o instrumento do Institute for Healthcare Improvement (IHI) adaptado para a realidade local, que inclui rastreadores medicamentosos, bioquímicos e clínicos. Foram coletadas variáveis demográfico-clínicas, relativas ao regime terapêutico, exames laboratoriais, intervenções durante a internação e sinais/sintomas clínicos. A variável dependente foi a ocorrência de EAM. Os dados foram analisados por meio dos testes Qui-quadrado, Exato de Fisher, Correlação de Pearson e regressão logística multivariada, com significância de p0,05. Resultados: A incidência de pacientes com EAM foi 22,3% e o número de EAM por 100 pacientes foi 32,3, média de 1,4 EAM. A amostra foi composta predominantemente por homens (54,6%), idosos jovens (68,8%), internados para procedimentos clínicos (67,4%) e sujeitos a polifarmácia (70,6%). Sangramento (21,7%), injúria renal aguda (20%), hipotensão (18,3%), náusea/vômito (15%) e hipoglicemia (13,3%) foram os EAM mais frequentes. Identificou-se correlação positiva entre EAM e as variáveis comorbidades (r=0,189), tempo de internação (r=0,288) e número de medicamentos prescritos (r=0,282). Os fatores de risco para EAM em UTI foram ventilação mecânica (OR= 2,614; IC95% 1,393 4,906; p= 0,003), injúria renal aguda (OR= 3,794; IC95% 1,688 8,527; p=0,001) e diabetes mellitus (OR= 3,280; IC 95% 1,703 6,315; p= 0,000). Conclusão: A ocorrência dos EAM mostrou-se correlacionada positivamente com atributos que são muito característicos de idosos admitidos em UTI, aspecto que pode servir de alerta aos profissionais que realizam o monitoramento desses eventos. / Introduction: Adverse drug events (ADE) represent an important public health problem, being associated with morbidity and mortality, a higher hospital stay rate and higher costs. The elderly and intensive care patients (ICU) are at risk groups for the occurrence of these events. The use of trackers, which represent situations indicative of potential ADE, simplifies the detection of ADE through the systematic screening of medical records, making it possible to measure the rate of these adversities continuously and to advance in the practice of critical patient safety. Objective: To analyze adverse drug events and associated factors in elderly ICU patients. Method: Retrospective cohort conducted with elderly patients admitted to ICU at Hospital das Clínicas, Medical School, University of São Paulo. The consecutive sample consisted of records of the elderly, hospitalized for at least 24 hours for clinical or surgical treatment and who received at least one medication. Patients were followed up for ICU discharge or discharge. The Institute for Healthcare Improvement (IHI) instrument adapted to the local reality, which includes drug, biochemical and clinical trackers, was used to identify the ADE. Demographic and clinical variables related to the therapeutic regimen and laboratory tests, therapeutic interventions during hospitalization, clinical signs and symptoms were collected. The dependent variable was the occurrence of ADE. Data were analyzed using the Chi-square test, Fisher\'s exact test, Pearson\'s correlation and multivariate logistic regression, with significance of p0.05. Results: The incidence of ADE patients was 22.3% and the number of ADE per 100 patients was 32.3, a mean of 1.4 ADE. Men (54.6%), young adults (68.8%), hospitalized for clinical procedures (67.4%) and polypharmacy (70.6%). Bleeding (21.7%), acute renal injury (20%), hypotension (18.3%), nausea / vomiting (15%) and hypoglycaemia (13.3%) were the most frequent events. A positive correlation between EAM and comorbidities (r = 0.189), length of hospital stay (r = 0.288), and number of drugs prescribed (r=0.282) were identified. The risk factors for EAM in the ICU were mechanical ventilation (OR= 2,614; IC95%, 1,393 4,906; p= 0,003), acute renal injury (OR= 3,794; IC95% 1,688 8,527; p=0,001) and diabetes mellitus (OR= 3,280; IC 95% 1,703 6, 315; p= 0,000). Conclusion: The occurrence of ADE was positively correlated with attributes that are very characteristic of the elderly admitted to the ICU, an aspect that can serve as an alert to the professionals who perform the monitoring of these events.
|
Page generated in 0.0347 seconds